Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

British journal of clinical pharmacology - 1 May 2007

Lefebvre Jean, Poirier Luc, Poirier Paul, Turgeon Jacques, Lacourciere Yves

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * The variability in drug metabolism has been recognized as an important factor in the occurrence of adverse effects or lack of therapeutic efficacy. * The metabolism of the third-generation beta(1)-receptor antagonist nebivolol has been shown to be highly dependent on cytochrome P450 2D6 enzymatic activity in preclinical studies. WHAT THIS STUDY ADDS: * This paper...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Benzopyrans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Pressure

Share to Cytochrome P-450 CYP2D6

Share to Ethanolamines

Share to Heart Rate

Share to Single-Blind Method

Share to Vasodilator Agents

Source

Open in PubMed Open full text

Identifiers

PMID: 17094780
DOI: 10.1111/j.1365-2125.2006.02796.x
PMCID: PMC2000751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.PMID 17094780Read ↗

Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.Semantic proximity Read ↗

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Semantic proximity Read ↗

Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.Semantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.Semantic proximity Read ↗

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.Semantic proximity Read ↗

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Semantic proximity Read ↗

Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro.Semantic proximity Read ↗

Miotic action of tramadol is determined by CYP2D6 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.